IDEAYA Biosciences Inc.

**Baker Bros. Initiates Large New Position in IDEAYA Biosciences (IDYA)** Baker Bros. built a substantial new position of ~3.6M shares in IDYA, signaling high-conviction backing of IDEAYA's lead asset darovasertib (PKC inhibitor) in metastatic uveal melanoma, where Phase 3 data readouts are anticipated and the drug addresses a tumor type with no approved targeted therapies. Baker's concentrated, specialist approach — they typically run fewer than 30 names at size — makes any new initiation notable, and the scale here suggests they see a favorable risk/reward ahead of pivotal catalysts. This is consistent with strengthening clinical data in the MAT2A and synthetic lethality pipeline as well, but the uveal melanoma opportunity likely drives the position sizing.